Totect Approval History
- FDA approved: Yes (First approved September 6th, 2007)
- Brand name: Totect
- Generic name: dexrazoxane
- Company: TopoTarget A/S
- Treatment for: Anthracycline Extravasation
Totect (dexrazoxane) is a topoisomerase inhibitor used as a detoxifying agent for the treatment of extravasation resulting from intravenous anthracycline chemotherapy.
Development History and FDA Approval Process for Totect
|Sep 7, 2007||Totect Approved in the United States|
|May 31, 2007||TopoTarget elaborates on the specific initiatives to obtain FDA approval of Totect|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.